NASDAQ · PRPH
Healthcare · Drug Manufacturers - Specialty & Generic
$0.02
Down-$0.01 (-33.33%)
Updated Aug 23, 2026, 9:04 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
PRPH does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning PRPH.
PRPH research
Company profile and research snapshot.
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 21, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 10, 2023 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2023 | HC Wainwright & Co. | Buy | — |
| Jun 2, 2023 | HC Wainwright & Co. | Buy | — |
| May 12, 2023 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 19, 2026
ProPhase Labs (OTC:PRPH) reported quarterly losses of $(0.22) per share. This is a 79.63 percent increase over losses of $(1.08) per share from the same period last year. The company reported $1.011 million in sales
Benzinga · Jun 30, 2026
ProPhase Labs (OTC:PRPH) reported quarterly losses of $(0.43) per share. This is a 67.67 percent increase over losses of $(1.33) per share from the same period last year. The company reported $478.000 thousand in sales
Finnhub · Apr 15, 2026
ProPhase Labs, Inc. reported earnings results for the full year ended December 31, 2025. For the full year, the company reported sales was USD 4.9 million compared to USD 6.77 million a year ago. Net...
Finnhub · Apr 15, 2026
$201.2 Million in Gross Claims with Expanding Settlement Activity Across Multiple Insurance Carriers Active Negotiations Support Estimated $50–$60 Million Net Recovery and Near-Term Cash Flow...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRPH.
